Company Overview and News

The heat is on for TH Heavy Engineering

2018-10-16 theedgemarkets
OCT 26 is the deadline for TH Heavy Engineering Bhd (THHE) to submit its regularisation plan to Bursa Malaysia, which is crucial for it to exit Practice Note 17 (PN17) status, a category for financially distressed companies.
7206 5241 BSMAF 1818

Boardroom changes at Bonia

2018-08-28 theedgemarkets
KUALA LUMPUR (Aug 28): Bonia Corp Bhd founder Chiang Sang Sem will leave his position as group executive chairman and chief executive officer effective Sept 1.
5241 BSMAF 1818

Sona Petroleum to delist on Thursday

2018-06-26 theedgemarkets
KUALA LUMPUR: Sona Petroleum Bhd will be delisted from Bursa Malaysia on Thursday, June 28, the company said yesterday.
5241 BSMAF 1818

Sona Petroleum to de-list Thursday

2018-06-25 theedgemarkets
KUALA LUMPUR (June 25): Sona Petroleum Bhd will be de-listed from Bursa Malaysia on Thursday, June 28, the company said today.
5241 BSMAF 1818

Red Sena weakness presents buying opportunity

2018-06-11 theedgemarkets
KUALA LUMPUR: Recent weakness in Red Sena Bhd shares, as the food and beverage (F&B) special purpose acquisition company’s (SPAC) mandated requirement of making a qualifying acquisition (QA) remains elusive, has created a good buying opportunity.
5270 5241 BSMAF 5256 5234 1818

Sona Petroleum to distribute monies to shareholders in April

It was reported in December 2013, that Sona was eyeing a new oil field asset in Indonesia to buy after failing to clinch a deal in September.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...